Phase-3 trials find 1-shot chikungunya vaccine safe: Lancet

The first chikungunya vaccine may be on its way with phase 3 trials of a single-shot jab developed by French biotech company Valneva showing the vaccine to be generally safe, well tolerated and provoking an immune response. The study was conducted in the US. Its success will have significant implications for nations like India where chikungunya is endemic.

June 13, 2023 at 12:59AM

from Times of India

https://ift.tt/0PQkGZ1

No comments:

Post a Comment

Is chewing food linked with a long and healthy life?

Chewing food thoroughly is crucial for digestion, nutrient absorption, and overall health. While the ideal number of chews varies, aiming fo...